FAQ on Lantern Pharma's AI-Driven Oncology Pipeline and Corporate Communications Strategy

What is Lantern Pharma’s focus in oncology drug development?

Lantern Pharma focuses on accelerating precision oncology drug development using its proprietary RADR(R) AI platform, which leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to target various cancers, including lung, brain, breast, and blood cancers.

Why has Lantern Pharma engaged IBN?

Lantern Pharma has engaged IBN to lead its corporate communications strategy to expand investor awareness as the company pursues key milestones across its data-driven, biomarker-informed pipeline of cancer therapies.

What are some of the cancers Lantern Pharma’s therapies target?

Lantern Pharma’s therapies target lung, brain, breast, and blood cancers, including three AI-guided candidates and a CNS-focused subsidiary, with multiple FDA-designated therapies in active trials.

How does Lantern Pharma’s RADR(R) AI platform contribute to drug development?

The RADR(R) AI platform accelerates drug development by analyzing over 200 billion oncology-focused data points with more than 200 advanced ML algorithms, reducing the time and cost to bring new drugs to clinical trials to approximately 2-3 years and $2.5 million per program.

Where can I find more information about Lantern Pharma’s latest updates?

The latest news and updates relating to Lantern Pharma (LTRN) are available in the company’s newsroom at https://ibn.fm/LTRN.

What is the significance of Lantern Pharma’s partnership with IBN?

The partnership with IBN is significant as it aims to enhance Lantern Pharma’s corporate communications and investor awareness, crucial for advancing its AI-driven oncology pipeline and achieving key clinical milestones.

How does Lantern Pharma’s approach compare to traditional oncology drug development?

Lantern Pharma’s AI-driven approach significantly reduces the cost and time of oncology drug development, advancing programs from initial AI insights to first-in-human clinical trials in 2-3 years at approximately $2.5 million per program, compared to the longer timelines and higher costs associated with traditional methods.

What are the implications of Lantern Pharma’s AI-driven oncology pipeline?

Lantern Pharma’s AI-driven oncology pipeline represents a transformative approach to cancer treatment, offering the potential for more precise, efficient, and cost-effective development of therapies targeting a wide range of cancers.